7-((3,4-dimethoxyphenethyl)amino)-3,4,5,5a-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one | 1020003-60-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 7-((3,4-dimethoxyphenethyl)amino)-3,4,5,5a-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one
• CAS: 1020003-60-4
• 化学式: C₂₀H₂₁N₃O₃
• 分子量: 351.405
• InChiKey: IZSPZNFPYIQWQG-UHFFFAOYSA-N

反应信息

• 作为产物：
  描述：

  在 sodium methylate 作用下， 以 甲醇 为溶剂， 以41 mg的产率得到7-((3,4-dimethoxyphenethyl)amino)-3,4,5,5a-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one
  参考文献：
  名称：

  makaluvamines的苄基和苯乙基类似物的合成及其抗增殖活性。

  摘要：

  合成了带有取代的苄基和取代的苯乙基侧链的海洋生物碱，makaluvamine的类似物，并评估了它们的抗增殖活性。4-甲基，4-氯和4-氟取代的苄基类似物在乳腺癌细胞系MCF-7的IC（50）值分别为2.3 microM，1.8 microM和2.8 microM时具有明显的抗增殖作用。4-甲基，4-氯和3,4-亚甲二氧基衍生物在苯乙基类似物中表现出对MCF-7的最佳活性，其IC（50）值分别为2.3 microM，2.8 microM和2.4muM。通常，在苄基和苯乙基系列中，甲氧基取代都会导致活性的轻微损失。苄基，4-氟苄基，3,4-二甲氧基苯乙基和3，通过NCI在其60个细胞系的体外人类癌细胞筛选中测试了4-亚甲基二氧基苯乙基类似物。所有四种化合物对几种测试的癌细胞系均表现出优异的抑制作用。苄基和4-氟苄基类似物比3,4-二甲氧基苯乙基和3,4-亚甲二氧基苯乙基类似物具有更高的活性。在

  DOI：

  10.1016/j.bmc.2007.11.051

文献信息

• Azide-Mediated Detosylation of <i>N</i>-Tosylpyrroloiminoquinones and <i>N</i>-Tosylindole-4,7-quinones
  作者：Sadanandan Velu、Swayamprabha Patel、Dwayaja Nadkarni、Srinivasan Murugesan、Jason King

  DOI：10.1055/s-0028-1083570

  日期：——

  The utility of NaN3 as a reagent for the detosylation of N-tosylpyrroloiminoquinones and N-tosylindole-4,7-quinones is described. The NaN3-mediated detosylation is carried out in polar aprotic solvents such as DMF and DMSO. The reaction occurs under neutral, mild conditions and results in good to excellent yields of the detosylated quinones.

  NaN3作为N-甲苯磺酰吡咯并咪诺喹啉和N-甲苯磺酰吲哚-4,7-喹啉脱甲苯磺酰化反应试剂的实用性已经得到了描述。在极性质子惰性溶剂如DMF和DMSO中进行NaN3介导的脱甲苯磺酰化反应。该反应在温和中性条件下进行，并能获得较好的至优异的脱甲苯磺酰化喹啉产率。
• Marine Alkalod Makaluvamines and Derivatives Thereof
  申请人：Velu Sadanandan E.

  公开号：US20100144779A1

  公开（公告）日：2010-06-10

  The present disclosure provides compounds based on the marine alkaloid makaluvamine. Described are compounds of the general formula (I) and (II). Also described are pharmaceutical compositions comprising one or more of the compounds of the general formula (I) and (II). The compounds and pharmaceutical compositions described inhibit the growth of several cancer lines, induce apoptosis and cell cycle arrest, display topoisomerase II inhibitory activity and modulate the activity and/or expression of key proteins involved in the regulation of cell growth. Methods of treatment and prevention using the compounds and pharmaceutical compositions described are also provided.
• [EN] MARINE ALKALOID MAKALUVAMINES AND DERIVATIVES THEREOF<br/>[FR] ALCALOÏDES MAKALUVAMINES MARINS ET LEURS DÉRIVÉS
  申请人：UAB RESEARCH FOUNDATION

  公开号：WO2008103483A2

  公开（公告）日：2008-08-28

  [EN] The present disclosure provides compounds based on the marine alkaloid makaluvamine. Described are compounds of the general formula (I) and (II). Also described are pharmaceutical compositions comprising one or more of the compounds of the general formula (I) and (II). The compounds and pharmaceutical compositions described inhibit the growth of several cancer lines, induce apoptosis and cell cycle arrest, display topoisomerase II inhibitory activity and modulate the activity and/or expression of key proteins involved in the regulation of cell growth. Methods of treatment and prevention using the compounds and pharmaceutical compositions described are also provided.
  [FR] La présente invention concerne des composés fondés sur l'alcaloïde makaluvamine marin. Les composés de formule générale (I) et (II) sont décrits. L'invention concerne également des compositions pharmaceutiques comprenant un ou plusieurs des composés de formule générale (I) et (II). Les composés et les compositions pharmaceutiques décrits inhibent la croissance de plusieurs lignées cancéreuses, induisent l'apoptose et stoppent le cycle cellulaire, affichent une activité d'inhibition de la topoisomérase II et modulent l'activité et/ou l'expression de protéines clés impliquées dans la régulation de la croissance cellulaire. L'invention concerne également des procédés de traitement et de prévention qui utilisent les composés et les compositions pharmaceutiques décrits.